World Equity Group’s Myriad Genetics MYGN Stock Holding History

World Equity Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-21,858	Closed	-$230K	–	462
2023 Q1	$230K	Buy	+21,858	New	+$444K	0.03%	430

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

World Equity Group's MYGN Position: Q2 2023 in Review

World Equity Group sold out of Myriad Genetics (MYGN) in Q2 2023, closing a stake of 21,858 shares — an estimated $230K sold.

World Equity Group first reported a position in MYGN in Q1 2023 and held it in 1 quarter. The position peaked at $230K in Q1 2023. 188 funds tracked by Wall St. Rank hold MYGN as of Q2 2023.

World Equity Group reported no remaining Myriad Genetics position as of Q2 2023 after selling out during the quarter.
World Equity Group sold 21,858 Myriad Genetics shares in Q2 2023, an estimated $230K.
World Equity Group first reported a position in Myriad Genetics in Q1 2023 and held it in 1 quarter.
World Equity Group's Myriad Genetics position peaked at $230K in Q1 2023.
188 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2023.

Based on World Equity Group's 13F filing for Q2 2023, filed 26 Aug 2024.